FDA Approves Emicizumab-kxwh for Prevention and Reduction of Bleeding in Patients With Hemophilia A With Factor VIII Inhibitors
Nov 15
2017
The Food and Drug Administration approved emicizumab-kxwh (HEMLIBRA®, Genentech, Inc.) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
